Skip to main content
Uday Dandamudi, MD, Oncology, Trinity, FL

UdayDandamudiMD

Oncology Trinity, FL

Hematologic Oncology

Physician

Dr. Dandamudi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Dandamudi's full profile

Already have an account?

  • Office

    9320 State Road 54
    Trinity, FL 34655
    Phone+1 727-493-2513
    Fax+1 877-917-2336

Education & Training

  • Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital
    Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2009 - 2012
  • Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital
    Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Clinical Pharmacology, 2007 - 2009
  • Westchester Medical Center
    Westchester Medical CenterResidency, Internal Medicine, 1998 - 2000
  • Edgewater Hospital
    Edgewater HospitalResidency, Internal Medicine, 1997 - 1998
  • Edgewater Hospital
    Edgewater HospitalInternship, Internal Medicine, 1997 - 1998
  • Gandhi Medical College
    Gandhi Medical CollegeClass of 1994

Certifications & Licensure

  • NH State Medical License
    NH State Medical License 2007 - Present
  • FL State Medical License
    FL State Medical License 2012 - 2026
  • NY State Medical License
    NY State Medical License 2001 - 2008
  • IL State Medical License
    IL State Medical License 1997 - 2000
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Phase-I dose escaIatìon study of cycIIcaI Weekly Temozolomide (TMZ) combined with weekly PegyIated Interferon AIfa-Zb (PEG-IFN) in patients (pts) with refractory and...
    Dandamudi UB. BeeIan AP, Reddy NJ, Crosby NC, Ernstoff IVIS & Lewis LD, CIin Pharm & Ther
  • Comparative study of CYPZCQ and VKORC1 (-1639G>A) genotyping with the Nanopshere Verigene System and the Third VVave Gtechnologies invaderAssay.
    Dandamudi UB, Lefferts JA, Schwab MC, Bean JR, Lee HK, Tsongalis GJ, Lewis LD, The lXth World Conference on Clinical
  • Effect of oral (PO) casopitant, a novel NK~1 receptor antagonist, on the pharmacokinetics (PK) and safety profile of intravenous (IV) docetaxel.
    Adams L, Johnson B, Bauman J, Lebowitz P, Zhang, K. Webb, T. Gartner, E. Hohl R, Dandamudi UB. & Lewis, L, EJC Supplements Iss
  • Join now to see all

Professional Memberships